Loading...
A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer.
Hamilton, E Patel, M Armstrong, Anne C Baird, R Jhaveri, K Hoch, M Klinowska, T Lindemann, J Morgan, S Schiavon, G
Hamilton, E
Patel, M
Armstrong, Anne C
Baird, R
Jhaveri, K
Hoch, M
Klinowska, T
Lindemann, J
Morgan, S
Schiavon, G
Citations
Altmetric:
Abstract
AZD9496 is an oral non-steroidal, small-molecule inhibitor of estrogen receptor alpha (ERα), and a potent and selective antagonist and degrader of ERα. This first in human Phase 1 study determined the safety and tolerability of ascending doses of oral AZD9496 in women with estrogen receptor (ER)+/HER2- advanced breast cancer, characterized its pharmacokinetic (PK) profile, and made preliminary assessment of antitumor activity.
Description
Date
2018-02-13
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 827.23 KB
Keywords
Type
Article
Citation
A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer. 2018, Clin Cancer Res